Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

'Delta variant 60pc more transmissible than Alpha'

The Delta coronavirus variant of concern, first identified in India, is believed to be 60 per cent more transmissible than the Alpha variant which was previously dominant in Britain, a prominent UK epidemiologist said on Wednesday (June 9).

Neil Ferguson of Imperial College told reporters that estimates of Delta's transmission edge over Alpha had narrowed, and "we think 60 per cent is probably the best estimate".


Ferguson said that modelling suggested any third wave of infections could rival Britain's second wave in the winter - which was fuelled by the Alpha variant first identified in Kent, south east England.

But it was unclear how any spike in hospitalisations would translate into a rise in deaths, as more detail was needed on how well the vaccine protects against serious illness from Delta.

"It's well within possibility that we could see another third wave at least comparable in terms of hospitalisations," he said.

"I think deaths probably would be lower, the vaccines are having a highly protective effect... still it could be quite worrying. But there is a lot of uncertainty."

Britain has seen over 127,000 deaths within 28 days of a positive Covid-19 test, but has given more than three-quarters of adults a first dose of Covid-19 vaccine.

Public Health England has shown that the Delta variant reduces the effectiveness of Pfizer and AstraZeneca shots among those who have only received one shot, though protection is higher for those who have received both doses.

Ferguson said that up to a quarter of the Delta variant's transmissibility edge over Alpha might come from its immune escape from vaccines, saying it was "a contribution but not an overwhelming contribution" to its advantage.

More For You

Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less
Pharma industry group unhappy with NHS drug pricing offer

The ABPI warned that £2 billion of potential investment could be under risk

Pic credit: istock

Pharma industry group unhappy with NHS drug pricing offer

The Association of the British Pharmaceutical Industry (ABPI) has rejected the UK government’s offer to cut the cost of NHS drugs pricing scheme as it felt it was inadequate.

The industry group warned that £2 billion of potential investment could be under risk and wanted prime minister Keir Starmer to intervene, The Times reports.

Keep ReadingShow less
Day Lewis celebrates 50 years of delivering care to communities

The Patel family at the unveiling of the commemorative plaque ceremony

Day Lewis celebrates 50 years of delivering care to communities

Day Lewis honoured "the people, purpose and partnerships" as it celebrated 50 years of service by unveiling a commemorative plaque at the company’s support office in Croydon.

As one of the UK’s largest independent pharmacy chains, Day Lewis has delivered trusted care to communities across the country since it was founded in 1975, by brothers Kirit and JC Patel, who was on hand to unveil the plaque.

Keep ReadingShow less
CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

Pic credit: iStock

Pharmacy owners asked to share views on new contract and its financial implications

Pharmacy owners can share their thoughts on service developments and their financial security before the upcoming Community Pharmacy England (CPE) committee meeting to be held on June 25 and 26.

The new Community Pharmacy Contractual Framework (CPCF) was completed in March with the various service and regulatory changes still in progress.

Keep ReadingShow less
Cancer treatment impact

There have been supply issues with Creon since the summer of 2024

Pic credit: iStock

Cancer patients struggle amid digestive drug shortage

Pharmacists in the Channel Islands have revealed that there is a shortage of a drug used to support digestion in cancer patients.

Creon is a pancreatic enzyme replacement therapy (PERT), which helps people living with conditions such as cystic fibrosis, pancreatitis, and pancreatic cancer to digest food.

Keep ReadingShow less